Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases.

Kim YH, Song Y, Kim JK, Kim TM, Sim HW, Kim HL, Jang H, Kim YW, Hong KM.

PLoS One. 2019 Sep 12;14(9):e0222535. doi: 10.1371/journal.pone.0222535. eCollection 2019.

2.

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS.

Thorac Cancer. 2019 Sep 11. doi: 10.1111/1759-7714.13195. [Epub ahead of print]

PMID:
31509890
3.

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.

Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, Kim KH, Kim JS, Kim TM, Kim DW, Lee JS, Heo DS.

Lung Cancer. 2019 Aug 29;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. [Epub ahead of print]

PMID:
31494530
4.

Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.

Kim N, Chang JS, Wee CW, Kim IA, Chang JH, Lee HS, Kim SH, Kang SG, Kim EH, Yoon HI, Kim JW, Hong CK, Cho J, Kim E, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Kim IH, Suh CO.

Strahlenther Onkol. 2019 Sep 5. doi: 10.1007/s00066-019-01512-y. [Epub ahead of print]

PMID:
31489457
5.

Expansion of EHR-Based Common Data Model (CDM).

Choi W, Ko SJ, Jung HJ, Kim TM, Choi I.

Stud Health Technol Inform. 2019 Aug 21;264:1443-1444. doi: 10.3233/SHTI190475.

PMID:
31438172
6.

High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Kim S, Nam SJ, Park C, Kwon D, Yim J, Song SG, Ock CY, Kim YA, Park SH, Kim TM, Jeon YK.

Oncoimmunology. 2019 Jun 10;8(9):e1626653. doi: 10.1080/2162402X.2019.1626653. eCollection 2019.

PMID:
31428525
7.

Eriobotrya japonica leaf extract attenuates airway inflammation in ovalbumin-induced mice model of asthma.

Kim TM, Paudel KR, Kim DW.

J Ethnopharmacol. 2019 Jul 13:112082. doi: 10.1016/j.jep.2019.112082. [Epub ahead of print]

PMID:
31310829
8.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.

PMID:
31221619
9.

Generation of mesenchymal stem-like cells for producing extracellular vesicles.

Kim S, Kim TM.

World J Stem Cells. 2019 May 26;11(5):270-280. doi: 10.4252/wjsc.v11.i5.270. Review.

10.

First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.

Kim R, Keam B, Hahn S, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11.

PMID:
31164319
11.

Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.

Lee JJ, Park S, Park H, Kim S, Lee J, Lee J, Youk J, Yi K, An Y, Park IK, Kang CH, Chung DH, Kim TM, Jeon YK, Hong D, Park PJ, Ju YS, Kim YT.

Cell. 2019 Jun 13;177(7):1842-1857.e21. doi: 10.1016/j.cell.2019.05.013. Epub 2019 May 30.

PMID:
31155235
12.

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.

Lee Y, Kim TM, Kim DW, Kim S, Kim M, Keam B, Ku JL, Heo DS.

J Thorac Oncol. 2019 Sep;14(9):1556-1566. doi: 10.1016/j.jtho.2019.05.006. Epub 2019 May 17.

PMID:
31108249
13.

NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.

Park HR, Ahn YO, Kim TM, Kim S, Kim S, Lee YS, Kim M, Keam B, Kim DW, Heo DS.

Cytotherapy. 2019 Jun;21(6):603-611. doi: 10.1016/j.jcyt.2019.03.312. Epub 2019 Apr 20.

PMID:
31010733
14.

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Choi M, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.

PMID:
31010639
15.

Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.

Kim WJ, Dho YS, Ock CY, Kim JW, Choi SH, Lee ST, Kim IH, Kim TM, Park CK.

J Neurooncol. 2019 Jun;143(2):321-328. doi: 10.1007/s11060-019-03167-2. Epub 2019 Apr 13.

PMID:
30982199
16.

Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.

Kim TM, Ko YH, Ha SJ, Lee HH.

BMC Cancer. 2019 Feb 4;19(1):119. doi: 10.1186/s12885-019-5332-y.

17.

Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.

Jung M, Kim S, Lee JK, Yoon SO, Park HS, Hong SW, Park WS, Kim JE, Kim J, Keam B, Kim HJ, Kang HJ, Kim DW, Jung KC, Kim YT, Heo DS, Kim TM, Jeon YK.

Oncologist. 2019 Aug;24(8):e740-e748. doi: 10.1634/theoncologist.2018-0477. Epub 2019 Jan 29.

PMID:
30696721
18.

MicroRNA-29a activates a multi-component growth and invasion program in glioblastoma.

Zhao Y, Huang W, Kim TM, Jung Y, Menon LG, Xing H, Li H, Carroll RS, Park PJ, Yang HW, Johnson MD.

J Exp Clin Cancer Res. 2019 Jan 25;38(1):36. doi: 10.1186/s13046-019-1026-1.

19.

Pruritus in Patients Under Targeted Anticancer Therapy: A Multidimensional Analysis Using the 5-D Itch Scale.

Cho SI, Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Jo SJ.

Acta Derm Venereol. 2019 Apr 1;99(4):435-441. doi: 10.2340/00015555-3129.

20.

Optimal Kiloelectron Volt for Noise-Optimized Virtual Monoenergetic Images of Dual-Energy Pediatric Abdominopelvic Computed Tomography: Preliminary Results.

Kim TM, Choi YH, Cheon JE, Kim WS, Kim IO, Park JE, Shin SM, Pak SY, Krauss B.

Korean J Radiol. 2019 Feb;20(2):283-294. doi: 10.3348/kjr.2017.0507.

21.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS.

Cancer Res Treat. 2019 Jul;51(3):1231-1240. doi: 10.4143/crt.2018.486. Epub 2018 Dec 31.

22.

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.

Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, Kim YJ, Kim TM, Jeon YK, Kim DW, Chung DH, Lee JS, Heo DS.

BMC Cancer. 2019 Jan 7;19(1):19. doi: 10.1186/s12885-018-5214-8.

23.

Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE).

Kim HS, Lee SH, Kim TM, Kim JH.

Clin Hypertens. 2018 Dec 15;24:18. doi: 10.1186/s40885-018-0103-7. eCollection 2018.

24.

Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes.

Kim K, Jeon S, Kim TM, Jung CK.

Cancers (Basel). 2018 Dec 5;10(12). pii: E494. doi: 10.3390/cancers10120494.

25.

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.

Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, Kim DW, Heo DS.

Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.

PMID:
30546955
26.

Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea.

Baik SY, Kim H, Yang SJ, Kim TM, Lee SH, Cho JH, Lee H, Yim HW, Yoon KH, Kim HS.

Front Med. 2018 Nov 27. doi: 10.1007/s11684-018-0661-9. [Epub ahead of print]

PMID:
30483915
27.

Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?

Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, Kwon TK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2018 Nov 16. doi: 10.3904/kjim.2017.397. [Epub ahead of print]

28.

Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Accelerate Skin Cell Proliferation.

Kim S, Lee SK, Kim H, Kim TM.

Int J Mol Sci. 2018 Oct 11;19(10). pii: E3119. doi: 10.3390/ijms19103119.

29.

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS.

Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10.

30.

Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.

Kim E, Wu HG, Keam B, Kim TM, Kim DW, Paeng JC, Kim HJ, Chang JH.

Clin Lung Cancer. 2019 Jan;20(1):e9-e23. doi: 10.1016/j.cllc.2018.08.018. Epub 2018 Aug 30.

PMID:
30266585
31.

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS.

Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.

32.

Persistent/Recurrent Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis.

Kim TM, Kim JH, Yoo RE, Kim SC, Chung EJ, Hong EK, Jo S, Kang KM, Choi SH, Sohn CH, Rhim JH, Park SW, Park YJ.

Thyroid. 2018 Nov;28(11):1490-1499. doi: 10.1089/thy.2018.0151. Epub 2018 Oct 16.

PMID:
30226443
33.

Renal Ischemia-Reperfusion Injury in a Diabetic Monkey Model and Therapeutic Testing of Human Bone Marrow-Derived Mesenchymal Stem Cells.

Lee KW, Kim TM, Kim KS, Lee S, Cho J, Park JB, Kwon GY, Kim SJ.

J Diabetes Res. 2018 Aug 1;2018:5182606. doi: 10.1155/2018/5182606. eCollection 2018.

34.

Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases.

Lee HH, Kim SY, Jung ES, Yoo J, Kim TM.

Gastric Cancer. 2019 Mar;22(2):323-334. doi: 10.1007/s10120-018-0870-6. Epub 2018 Aug 21.

PMID:
30132154
35.

Effect of Smoking on Healing Failure After Rotator Cuff Repair.

Park JH, Oh KS, Kim TM, Kim J, Yoon JP, Kim JY, Chung SW.

Am J Sports Med. 2018 Oct;46(12):2960-2968. doi: 10.1177/0363546518789691. Epub 2018 Aug 21.

PMID:
30129777
36.

Effect of sorghum ethyl-acetate extract on benign prostatic hyperplasia induced by testosterone in Sprague-Dawley rats.

Ryu JM, Jang GY, Park D, Woo KS, Kim TM, Jeong HS, Kim DJ.

Biosci Biotechnol Biochem. 2018 Dec;82(12):2101-2108. doi: 10.1080/09168451.2018.1507721. Epub 2018 Aug 18.

PMID:
30124113
37.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

38.

Clinical experiences and case review of angiotensin II receptor blocker-related angioedema in Korea.

Kim H, Baik SY, Yang SJ, Kim TM, Lee SH, Cho JH, Choi IY, Kim JH, Yoon KH, Kim HS.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):115-122. doi: 10.1111/bcpt.13097. Epub 2018 Aug 20.

PMID:
30003686
39.

Identification of local clusters of mutation hotspots in cancer-related genes and their biological relevance.

Rhee JK, Yoo J, Kim KR, Kim J, Lee YJ, Cho BC, Kim TM.

IEEE/ACM Trans Comput Biol Bioinform. 2018 Mar 16. doi: 10.1109/TCBB.2018.2813375. [Epub ahead of print]

PMID:
29993813
40.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2019 Sep;34(5):1116-1124. doi: 10.3904/kjim.2018.011. Epub 2018 Jun 29.

41.

Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.

Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH.

Radiother Oncol. 2018 Aug;128(2):254-259. doi: 10.1016/j.radonc.2018.05.024. Epub 2018 Jun 21.

PMID:
29937212
42.

Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.

Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, Kim CW, Jeon YK.

Oncoimmunology. 2018 Mar 13;7(7):e1442164. doi: 10.1080/2162402X.2018.1442164. eCollection 2018.

43.

Prevalence and Predictors of Patellofemoral Osteoarthritis after Anterior Cruciate Ligament Reconstruction with Hamstring Tendon Autograft.

Lee DW, Yeom CH, Kim DH, Kim TM, Kim JG.

Clin Orthop Surg. 2018 Jun;10(2):181-190. doi: 10.4055/cios.2018.10.2.181. Epub 2018 May 18.

44.

Improvement of Trehalose Production by Immobilized Trehalose Synthase from Thermus thermophilus HB27.

Sun J, Wang S, Li W, Li R, Chen S, Ri HI, Kim TM, Kang MS, Sun L, Sun X, Yuan Q.

Molecules. 2018 May 4;23(5). pii: E1087. doi: 10.3390/molecules23051087.

45.

Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.

Hong EK, Choi SH, Shin DJ, Jo SW, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park SH, Won JK, Kim TM, Park CK, Kim IH, Lee ST.

Eur Radiol. 2018 Oct;28(10):4350-4361. doi: 10.1007/s00330-018-5400-8. Epub 2018 May 2.

PMID:
29721688
46.

Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes.

Rhee JK, Kim TM.

BMC Med Genomics. 2018 Apr 20;11(Suppl 2):29. doi: 10.1186/s12920-018-0352-z.

47.

Refractory patellar tendinopathy treated by arthroscopic decortication of the inferior patellar pole in athletes: Mid-term outcomes.

Lee DW, Kim JG, Kim TM, Kim DH.

Knee. 2018 Jun;25(3):499-506. doi: 10.1016/j.knee.2018.02.015. Epub 2018 Apr 21.

PMID:
29685503
48.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

49.

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.

Zhang W, McIntyre C, Kuhn M, Forbes H, Kim TM, Lee J, Demidov L, Colburn D.

J Clin Pharmacol. 2018 Apr 12. doi: 10.1002/jcph.1111. [Epub ahead of print]

PMID:
29645280
50.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2019 Jan;51(1):169-177. doi: 10.4143/crt.2017.491. Epub 2018 Apr 5.

Supplemental Content

Support Center